How Targeted Cancer Treatment Imbruvica (Ibrutinib) Works Imbruvica (Ibrutinib) is a cancer treatment for certain types of blood and lymph node cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma. In this video, oncologist Stephen Lemon MD talks about how Imbruvica works, including what types of side effects may occur from this treatment. Visit to learn more about this blood cancer treatment. Taken orally by pill, this targeted therapy has shown in studies to help patients live without cancer spreading and live longer compared to patients not taking the drug. Ibrutinib is the trade name and Imbruvica is made by Pharmacyclics and Janssen Biotech. Dr. Stephen Lemon is a medical oncologist with Oncology Associates and is not affiliated with either company. Visit to learn more about Dr. Lemon and Oncology Associates. What is targeted therapy? Unlike standard chemotherapy which often attacks the patient's healthy cells along with the cancer cells, targeted therapy will go after the cancer cells, while doing less damage to the patient's normal cells. These cancer education videos are intended to provide further information on new or recent cancer drug treatments.